Emmaus Life Sciences Secures Exclusive Supply Agreement for Endari® with NeoImmuneTech
Summary
Emmaus Life Sciences signed an exclusive supply agreement with NeoImmuneTech for Endari® in North America, with terms including a double-digit margin, though its effectiveness is contingent on regulatory approvals.
Key Events
-
Exclusive Supply Agreement Signed
Emmaus Life Sciences and NeoImmuneTech, Inc. (NIT) entered into an Exclusive Supply Agreement on March 2, 2026, for Endari® in the U.S. and Canada.
-
Favorable Supply Terms
Emmaus will exclusively supply Endari® to NIT, and NIT will exclusively purchase from Emmaus, at a price based on Emmaus's cost of production plus a specified double-digit percentage margin.
-
Contingent Effective Date
The agreement's 'Effective Date' is subject to NIT obtaining necessary regulatory approvals and licensing, with no assurance it will occur by the October 1, 2026 deadline.
-
Follows Prior License Agreement
This supply agreement was contemplated by a License and Exclusive Distribution Agreement dated December 24, 2025, previously reported on December 31, 2025.
Analysis
Emmaus Life Sciences has entered into an exclusive supply agreement with NeoImmuneTech (NIT) for its sickle cell disease product, Endari®, in the U.S. and Canada. This agreement, which was contemplated by a prior license agreement from December 2025, establishes Emmaus as the sole supplier to NIT at a purchase price based on production cost plus a double-digit percentage margin. While this deal could provide a stable revenue stream and distribution channel for Emmaus, its effectiveness is contingent upon NIT obtaining necessary regulatory approvals and licensing by October 1, 2026, introducing a degree of uncertainty.
At the time of this filing, EMMA was trading at $0.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $926.1K. The 52-week trading range was $0.00 to $0.05. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.